Jennifer Michaelson sold $117k of CGEM
Chief Scientific Officer at Cullinan Therapeutics, Inc.. 8,000 shares at an average of $14.62, traded May 5, 2026, filed May 6, 2026.
Score components
- +15RoleOfficer
- +10Trade size$117k at market
- 0Share of holdings soldSold 4.6% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.9%, 3m +17.5%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-209307, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 5, 2026 | MOption exercise Common Stock10b5-1 | +4,000 | $4.30 | $17k | 174,844 | May 6, 2026 |
| May 5, 2026 | SOpen-market sale Common Stock10b5-1 | -7,800 | $14.60 | $114k | 167,044 | May 6, 2026 |
| May 5, 2026 | SOpen-market sale Common Stock10b5-1 | -200 | $15.58 | $3,116 | 166,844 | May 6, 2026 |
| May 5, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -4,000 | $0.00 | $0 | 116,987 | May 6, 2026 |
Related signals
Other insiders at Cullinan Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $173k 8,000 shares | -5% | |
| 5Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $608k 30,000 shares | -16% | |
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $143k 8,000 shares | -5% | |
| 6Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $125k 8,000 shares | -4% | |
| 15Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $25k 1,780 shares | -1% | |
| 52Moderate | Cullinan Therapeutics, Inc. | Nadim Ahmed President and CEO | $196k 13,515 shares | -3% | |
| 37Weak | Cullinan Therapeutics, Inc. | Jacquelyn L Sumer Chief Legal Officer | $52k 3,601 shares | -3% | |
| 38Weak | Cullinan Therapeutics, Inc. | Jeffrey Alan Jones Chief Medical Officer | $66k 4,582 shares | -3% | |
| 18Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $77k 5,353 shares | -3% | |
| 52Moderate | Cullinan Therapeutics, Inc. | Nadim Ahmed President and CEO | $223k 16,381 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.